Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs.
Portfolio
3
companies
Curve Therapeutics
Curve Therapeutics develops a Microcycle platform for intracellular cancer drug discovery.
Cyted Health
Cyted Health develops gastrointestinal molecular diagnostics for early esophageal disease detection.
Proximie
Proximie provides a digital health platform connecting operating rooms globally.
Shahzad Malik
General Partner
Shahzad is a general partner at Advent Life Sciences, having previously worked as an associate at McKinsey and an interventional cardiologist in the NHS. He also chairs the board of trustees for MQ: Transforming Mental Health.
LinkedIn
Kaasim Mahmood
General Partner
Kaasim brings venture capital experience, currently serving as a general partner at Advent Life Sciences after holding roles at Advent Venture Partners and Cutfield Freeman and Co.
LinkedInThe financing round was led by EQT Life Sciences alongside co-leads Advent Life Sciences and British Business Bank.
"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier. This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."
Pfizer Ventures led the financing round alongside Columbus Venture Partners and British Patient Capital.
"This financing will enable us to expand our team, progress our lead assets into the clinic and expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."
The Series C financing was led by Advent Life Sciences with backing from several new and existing institutional investors to accelerate product development and scale operations.
"We are delighted to partner with Proximie and a world class group of investors as the company expands its global footprint and product capabilities. The company is a perfect fit for our ethos of backing best-in-class innovative life sciences businesses that have the capability to positively impact human health and healthcare delivery in paradigm changing ways."
.png)